Allurion Technologies (ALUR) shares surged more than 81% premarket Friday after the company said overnight that it plans to initiate a combination clinical study to improve muscle mass and overall body composition.
The clinical trial will combine the Allurion Program, a weight-loss platform, with GLP-1 agonists. The latter are primarily used to manage Type 2 diabetes and obesity.
The study aims to prove that, by combining the Allurion Balloon and Allurion Virtual Care Suite with GLP-1 therapy, patients can "lose significant weight while increasing muscle mass and improving overall body composition," Allurion Chief Executive Shantanu Gaur said late Thursday.
Price: 6.73, Change: +3.03, Percent Change: +81.89
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。